This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Blood Test for Population Cancer Screening

Ticker(s): GRAL

Who's the expert?

Institution: Oncology Institute

  • Board-certified oncologist practicing medicine at the Oncology Institute of Hope and Innovation.
  • Manages 100 patients who are diagnosed with late-stage cancers per year. 25+ years in clinical practice, the majority spent serving as the Medical Directorfor Oncology/Hematology for Kaiser Permanente in San Diego.
  • Transitioned to the diagnostic industry where he has been the Medical Director for Hematology / Oncology forQuest Diagnostics and the Chief Medical Officer for Agendia, and Signal Genetics, bothmolecular diagnostics companies, and is a Special Consultant to the FDA on medical devices inc multi-analyte testing. 

Interview Goal
To gain a deeper understanding of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Blood Test for Population Cancer Screening

Are You Interested In These Questions?

Slingshot Insights Explained
1Day Left to Join Project
Call Date
Mar 31, 2026
Call Time
11:30 AM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.